SecurityTGTX / TG Therapeutics, Inc. (88322Q108)
CEO and PresidentWEISS MICHAEL S
Form 8-K Count103
Form 4 Count78
Form 10-Q Count20
Form SC 13G/A Count12

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TG Therapeutics, Inc.


7
TGTX / TG Therapeutics, Inc. null

2018-09-19 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5A
TGTX

8
TGTX / TG Therapeutics, Inc. null

2018-08-22 sec.gov - 1
 
TGTX

7
TGTX / TG Therapeutics, Inc. null

2018-08-22 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y [email protected] [email protected],C
TGTX

7
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D/A (Activist Investment)

2018-07-11 sec.gov
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

7
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D/A (Activist Investment)

2018-07-11 sec.gov
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

16
TGTX / TG Therapeutics, Inc. S-3

2018-07-09 sec.gov - 9
tgtx_s3v4.htm
TGTX

39
TGTX / TG Therapeutics, Inc. S-8

2018-06-25 sec.gov - 21
Blueprint As filed with the Securit
TGTX

20
18
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D AMENDMENT NO. 2 (Activist Investment)

2018-06-18 sec.gov
SC 13D Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

23
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D AMENDMENT NO. 2 (Activist Investment)

2018-06-18 sec.gov - 5
SC 13D Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

23
TGTX / TG Therapeutics, Inc. 8-K (Current Report)

2018-06-13 sec.gov - 5
Blueprint UNITED STATES
TGTX

27
20
18
TGTX / TG Therapeutics, Inc. null

2018-05-01 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5A
TGTX

21
TGTX / TG Therapeutics, Inc. PROXY NOTICE CARD

2018-04-30 sec.gov - 3
Untitled Document
TGTX

24
TGTX / TG Therapeutics, Inc. DEF14A

2018-04-30 sec.gov - 6
Blueprint UNITED STATES
TGTX

26
18
TGTX / TG Therapeutics, Inc. 10-K (Annual Report)

2018-03-15 sec.gov
Blueprint UNITED STATES
TGTX

 
TGTX / TG Therapeutics, Inc. / BRIDGER MANAGEMENT, LLC - 13G/A (Passive Investment)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)* TG Therapeutics, Inc. (Name of Issuer)   Common Stock, $0.001 Par Value (Title of Class of Securities)   88322Q108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d

 
TGTX / TG Therapeutics, Inc. / BRIDGER MANAGEMENT, LLC - 13G/A (Passive Investment)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)* TG Therapeutics, Inc. (Name of Issuer)   Common Stock, $0.001 Par Value (Title of Class of Securities)   88322Q108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d

 
TGTX / TG Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 4 TG THERAPEUTICS INC COMMON STOCK Cusip #88322Q108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88322Q108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 4,951,213 Item 8: 0 Item 9: 4,951,213 Item 11: 7.007% Item 12: HC Cusip #88322Q108 Item 1: Reporting Person - Abigail P.

 
TGTX / TG Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 4 TG THERAPEUTICS INC COMMON STOCK Cusip #88322Q108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88322Q108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 4,951,213 Item 8: 0 Item 9: 4,951,213 Item 11: 7.007% Item 12: HC Cusip #88322Q108 Item 1: Reporting Person - Abigail P.

 
TGTX / TG Therapeutics, Inc. V020218_8K (Current Report)

2018-02-02 sec.gov
Blueprint       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________   FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934     Date of report (Date of earliest event reported): February 2, 2018       TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)         Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identific

 
TGTX / TG Therapeutics, Inc. 8-K (Current Report)

2018-01-08 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): January 8, 2018   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TGTX / TG Therapeutics, Inc. 8-K (Current Report)

2017-12-12 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): December 11, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TGTX / TG Therapeutics, Inc. 8-K (Current Report)

2017-11-08 sec.gov
Blueprint     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________   FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934     Date of report (Date of earliest event reported): November 8, 2017       TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)         Delaware (State or Other Jurisdiction of Incorporation)                 001-32639                 (Commission File Number)   36-3

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-10-28 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): October 26, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-10-18 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): October 16, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-09-05 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): September 5, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-08-10 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): August 10, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-08-09 sec.gov
Blueprint     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________   FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934     Date of report (Date of earliest event reported): August 9, 2017       TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)         Delaware (State or Other Jurisdiction of Incorporation)                 001-32639                 (Commission File Number)   36-389

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-08-01 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): August 1, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-06-21 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): June 16, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-06-16 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): June 14, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics S-3

2017-06-09 sec.gov
tgtx_s3v4.htm As filed with the Securities and Exchange Commission on June 9, 2017 Registration No. 333-218293            UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TG THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter)     Delaware 36-3898269 (State or Other Jurisdiction of Incorporation or Organization) (I.

 
TG Therapeutics ESP

2017-07-19 sec.gov
      TG Therapeutics, Inc.   June 9, 2017   Securities and Exchange Commission Department of Corporation Finance Washington, D.C. 20549 Attn: Ms. Ada Sarmento     Via: EDGAR Submission     Re: TG Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-218293   Ladies and Gentlemen: TG Therapeutics, Inc. (the “Company”), hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 11:00 a.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-06-05 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): June 3, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

 
TG Therapeutics S-3

2017-05-26 sec.gov
tgtx_s3v4.htm     As filed with the Securities and Exchange Commission on May 26, 2017 Registration No. 333-             UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TG THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter)     Delaware 36-3898269 (State or Other Jurisdiction of Incorporation or Organization) (I.

 
TG Therapeutics 8-K (Current Report/Significant Event)

2017-05-24 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): May 23, 2017   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

TGTX : TG Therapeutics Stock Analysis and Research Report

2017-11-09 - Asif

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

Related News Stories

Your Daily Pharma Scoop: TGTX Positive Data In MS, Iovance Trial Delay

2018-10-12 seekingalpha
After its initial hiccup earlier with its CLL drug, this news should bolster the stock a little. (7-0)

Major Biopharma Catalysts to Watch For in October

2018-10-06 247wallst
Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-7)

Major Biopharma Catalysts on October’s FDA Calendar

2018-09-29 247wallst
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which can spell disaster for a stock, comes great reward as well. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-18)

Tyme Technologies (TYME) Shares March Higher, Can It Continue?

2018-09-28 zacks
As of late, it has definitely been a great time to be an investor in Tyme Technologies, Inc. (TYME - Free Report) . The stock has moved higher by 22.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. (16-0)

Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?

2018-09-28 zacks
Ra Pharmaceuticals, Inc. (RARX - Free Report) has been on the move lately as the stock has risen by 60.8% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue? (16-0)

CUSIP: 88322Q108